new bitcoin alternative, People also ask

If we can continue to cut interest rates in December, it will undoubtedly be a big plus for A shares, and the pressure on the exchange rate will be further reduced, which may become a turning point in the short term.The latest CPI data will be released tonight. The market expects the overall inflation rate to be 2.7%, 0.1 percentage point higher than that in October, and the core inflation rate is expected to be 3.3%, which is the same as that in October. Although the forecast data shows that the suppression of inflation by monetary policy is close to stagnation, it has dropped sharply compared with the previous peak of 9%. At present, the latest FEDWATCH data shows that the possibility of the Fed cutting interest rates next Tuesday is over 80%.The latest news of personal pension fund, incremental funds are coming!

This is a real long-term positive, which is manifested in three aspects: first, it is conducive to attracting investors to invest in the broad-based index through personal pension accounts; Second, it is helpful to inject new long-term funds into the capital market, optimize the investor structure, stabilize the market and promote the healthy development of the capital market; Third, it reflects the care of the regulatory authorities for the capital market and helps to enhance investors' confidence.Dizhe Pharmaceutical announced that the company's private placement plan has been approved by the Shanghai Stock Exchange. This is the first time that the refinancing of the unprofitable enterprise on the Shanghai Stock Exchange has been approved since the release of "Keba Article".Dizhe Pharmaceutical announced that the company's private placement plan has been approved by the Shanghai Stock Exchange. This is the first time that the refinancing of the unprofitable enterprise on the Shanghai Stock Exchange has been approved since the release of "Keba Article".

Dezhe Medicine is a listed company in science and technology innovation board, and it is an innovation-driven biomedical company with global competitiveness. Therefore, its refinancing has been approved by the Shanghai Stock Exchange, which also shows that the supervision is tolerant of companies with core technology and hard power. Although it may not be ideal financially for the time being, it has broad prospects and great imagination, which is worthy of support.So will heavyweights and large-cap stocks exert their strength? Looking at the trend of SSE 50, it is still very possible, because at present, the monthly trend of SSE 50 index is intact, and the index remains above the offensive line and above the long-term trend line. At present, it has the foundation to start a big market. Looking back, the index must remain above the monthly offensive line in all big markets, so this is a prerequisite. Since it is also available now, we can certainly expect something.Federal Reserve's December Outlook